Posts tagged international markets
New U.S. patent expands Mati's IP portfolio

Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment period. 

The patent, which expires in 2028, complements earlier issued U.S. patent claims directed to the proprietary punctal plug for non-invasive sustained delivery of topical drugs to the eye. The proprietary technology is used for multiple disease states with consistent, sustained efficacy.

Read More
BioSyent signs distribution pact for two CV products

BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market.

The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the products to Health Canada in 2016.

Read More